Publications
Selected publications
- Ultraviolet light-induced collagen degradation inhibits melanoma invasion. (Journal article - 2021)
- Female Immunity Protects from Cutaneous Squamous Cell Carcinoma. (Journal article - 2021)
- Prognostic gene expression signature for high-grade serous ovarian cancer. (Journal article - 2020)
2025
Stromal lipid species dictate melanoma metastasis and tropism.
Gurung, S., Budden, T., Mallela, K., Jenkins, B., von Kriegsheim, A., Manrique, E., . . . Virós, A. (2025). Stromal lipid species dictate melanoma metastasis and tropism.. Cancer cell, S1535-6108(25)00138-2. doi:10.1016/j.ccell.2025.04.001
2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Saner, F. A. M., Takahashi, K., Budden, T., Pandey, A., Ariyaratne, D., Zwimpfer, T. A., . . . Garsed, D. W. (2024). Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(16), 3481-3498. doi:10.1158/1078-0432.ccr-23-3552
2022
Molecular characterization of fast-growing melanomas.
Gaudy-Marqueste, C., Macagno, N., Loundou, A., Pellegrino, E., Ouafik, L., Budden, T., . . . Virós, A. (2022). Molecular characterization of fast-growing melanomas.. Journal of the American Academy of Dermatology, 86(2), 312-321. doi:10.1016/j.jaad.2021.07.011
2021
Female Immunity Protects from Cutaneous Squamous Cell Carcinoma.
Budden, T., Gaudy-Marqueste, C., Craig, S., Hu, Y., Hu, Y., Earnshaw, C. H., . . . Virós, A. (2021). Female Immunity Protects from Cutaneous Squamous Cell Carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(11), 3215-3223. doi:10.1158/1078-0432.ccr-20-4261
Ultraviolet light-induced collagen degradation inhibits melanoma invasion.
Budden, T., Gaudy-Marqueste, C., Porter, A., Kay, E., Gurung, S., Earnshaw, C. H., . . . Virós, A. (2021). Ultraviolet light-induced collagen degradation inhibits melanoma invasion.. Nature communications, 12(1), 2742. doi:10.1038/s41467-021-22953-z
Molecular subtype, biological sex and age shape melanoma tumour evolution.
Lotz, M., Budden, T., Furney, S. J., & Virós, A. (2021). Molecular subtype, biological sex and age shape melanoma tumour evolution.. The British journal of dermatology, 184(2), 328-337. doi:10.1111/bjd.19128
2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk, A., George, J., Wang, C., Budden, T., Tan, T. Z., Chiu, D. S., . . . Anglesio, M. S. (2020). Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(20), 5411-5423. doi:10.1158/1078-0432.ccr-20-0103
Prognostic gene expression signature for high-grade serous ovarian cancer.
Millstein, J., Budden, T., Goode, E. L., Anglesio, M. S., Talhouk, A., Intermaggio, M. P., . . . Ramus, S. J. (2020). Prognostic gene expression signature for high-grade serous ovarian cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 31(9), 1240-1250. doi:10.1016/j.annonc.2020.05.019
2019
MC1R CpG island regulates MC1R expression and is methylated in a subset of melanoma tumours.
Budden, T., & Bowden, N. A. (2019). MC1R CpG island regulates MC1R expression and is methylated in a subset of melanoma tumours.. Pigment cell & melanoma research, 32(2), 320-325. doi:10.1111/pcmr.12739
2018
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher, N. S., Schuster, K., Voss, A., Budden, T., Pang, C. N. I., deFazio, A., . . . Friedlander, M. L. (2018). Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.. Gynecologic oncology, 150(3), 527-533. doi:10.1016/j.ygyno.2018.07.013
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Budden, T., van der Westhuizen, A., & Bowden, N. A. (2018). Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.. BMC cancer, 18(1), 100. doi:10.1186/s12885-018-4010-9
2016
Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.
Budden, T., Davey, R. J., Vilain, R. E., Ashton, K. A., Braye, S. G., Beveridge, N. J., & Bowden, N. A. (2016). Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.. Oncotarget, 7(38), 60940-60953. doi:10.18632/oncotarget.10902
2013
The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis.
Budden, T., & Bowden, N. A. (2013). The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis.. International journal of molecular sciences, 14(1), 1132-1151. doi:10.3390/ijms14011132
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden, N. A., Ashton, K. A., Vilain, R. E., Avery-Kiejda, K. A., Davey, R. J., Murray, H. C., . . . Scott, R. J. (2013). Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.. PloS one, 8(8), e70424. doi:10.1371/journal.pone.0070424